(Q41107649)

26 September 2017

1 reference

title

Risks of parenteral deferoxamine for acute iron poisoning (English)

1 reference

26 September 2017

1 reference

Howland MA

1

1 reference

26 September 2017

1 January 1996

1 reference

Journal of Toxicology: Clinical Toxicology

26 September 2017

1 reference

26 September 2017

34

1 reference

26 September 2017

5

1 reference

26 September 2017

491-497

1 reference

Hemodynamic effects of experimental iron poisoning.

26 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Studies in Acute Iron Poisoning III. The Hemodynamic Alterations in Acute Experimental Iron Poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Iron: metabolism, toxicity and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

21 January 2018

Iron-chelating therapy

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Free radicals in toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

The role of iron in oxygen-mediated toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Ocular toxicity of high-dose intravenous desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Desferrioxamine, ocular toxicity, and trace metals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Ocular toxicity of desferrioxamine--an example of copper promoted auto-oxidative damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15563659609028006

10.3109/15563659609028006

21 January 2018

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

8800186